Gene therapy trial offers hope for hemophilia b patients

NCT ID NCT00979238

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new gene therapy for adults with severe hemophilia B, a bleeding disorder caused by a faulty gene. The treatment uses a harmless virus to deliver a working copy of the factor IX gene, aiming to reduce bleeding episodes. Fourteen participants received one of four doses to check safety and how well the therapy works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Katharine Dormandy Haemophilia Centre and Haemostasis Unit, University College of London

    London, United Kingdom

  • Scott and White Memorial Hospital

    Temple, Texas, 76508, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38119, United States

  • Stanford Medical School

    Stanford, California, 94305, United States